Second-line CML drugs evoke faster, better front-line remissions

Separate international phase III clinical trials compared high-quality remissions between previously untreated CML patients who took the standard-of-care drug imatinib and those on the second-generation drugs dasatinib and nilotinib. "The second-generation CML drugs are more effective than imatinib and less toxic overall," said one of the researchers.

Read the whole article on Science Daily

More from Science Daily